14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MDCX vs GRML: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 61.9/100 (BUY) at $1.68 (N/M Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDCX vs GRML. Trailing 12-month operating profitability (MDCX 0.0% vs GRML N/A) and valuation multiples (MDCX N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MDCX vs GRML Key Questions & Quantitative Answers
As of Nov 16, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 61.9/100 (BUY) at $1.68 (N/M Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin). Technically, MDCX sits in a Neutral phase (RSI 46.2, UNCLASSIFIED options structure) and GRML sits in a Neutral phase (RSI 37.5, UNCLASSIFIED options structure).
MDCX leads the Growth & Scale pillar: MDCX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MDCX generates N/A in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, MDCX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.
MDCX and GRML trade at balanced relative valuation multiples. MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDCX (-7446.1% ROE) versus GRML (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.42β · 108% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.